Equities

Hangzhou AGS MedTech Co Ltd

688581:SHH

Hangzhou AGS MedTech Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)48.00
  • Today's Change-14.00 / -22.58%
  • Shares traded518.46k
  • 1 Year change-40.58%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hangzhou AGS MedTech Co Ltd is a China-based company mainly engaged in the research, development, production and sales of endoscopic minimally invasive diagnostic and therapeutic devices. The Company's main products are used in the field of digestive endoscopy diagnosis and treatment, and are divided into hemostatic closure, EMR/ESD, biopsy, ERCP and diagnosis and treatment instruments according to their therapeutic purposes. The hemostatic closure category includes clip devices and single-use bipolar high-frequency hemostats. Medical instruments include high-frequency surgical equipment, carbon dioxide gas supply devices for endoscopes, and water supply devices for endoscopes. The biopsy category includes single-use biopsy forceps and single-use graspers.

  • Revenue in CNY (TTM)590.12m
  • Net income in CNY271.52m
  • Incorporated2010
  • Employees592.00
  • Location
    Hangzhou AGS MedTech Co LtdBuilding 5 and Building 6No. 597 Kangxin Road, Yuhang DistrictHANGZHOU 311106ChinaCHN
  • Phone+86 57 188775216
  • Fax+86 57 187671225
  • Websitehttp://www.bioags.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qingdao NovelBeam Technology Co Ltd413.02m124.91m4.52bn797.0036.133.53--10.951.041.043.4410.630.29620.86634.68518,221.708.8114.679.3716.6363.8562.3229.7334.159.12--0.026233.55-1.3118.58-20.1921.7110.45--
Jiangsu Bioperfectus Technologies Co Ltd394.84m-170.68m4.62bn684.00--1.41--11.70-2.91-2.916.7458.000.0970.97472.52577,244.10-4.1925.41-4.7431.2665.7063.37-43.2332.864.96--0.090330.54-92.7211.81-120.45--2.43--
TINAVI Medical Technologies Co Ltd168.49m-160.48m4.77bn339.00--4.04--28.30-0.3585-0.35850.37562.620.10751.484.73475,961.90-10.24-7.86-11.04-9.0768.6673.58-95.24-50.092.21--0.1532--34.4810.63-41.42--51.87--
Beijing Chunlizhengda Mdicl Instr Co Ltd924.65m158.35m4.88bn1.23k35.311.98--5.280.40780.40782.417.290.26980.53812.15751,138.904.6212.535.4915.4371.0872.7617.1226.893.80--0.000321.630.575919.40-9.7221.33-8.60--
Assure Tech Hangzhou Co Ltd590.49m90.50m4.91bn791.0054.270.9533--8.320.7120.7124.6540.530.10111.902.85746,504.601.5531.831.7138.9736.8765.8215.3047.868.66--0.012516.05-91.8425.18-95.3533.5178.77--
Zhejiang Gongdong Medical Techno Co Ltd1.10bn162.27m4.92bn1.67k30.342.96--4.481.031.036.9510.570.56846.554.33656,174.208.4016.359.7119.2632.4841.1914.7721.623.00--0.052138.99-33.6115.11-66.535.1427.71--
Hangzhou Ags Medtech Co Ltd590.12m271.52m5.01bn592.0018.452.17--8.503.363.367.3028.530.25453.2713.92996,828.3011.71--12.26--71.52--46.01--19.56--0.003--37.09--49.87------
Xiangyu Medical Co Ltd709.56m121.39m5.14bn1.82k41.732.54--7.250.770.774.5212.660.25961.0114.80390,085.104.4411.185.6213.1266.0366.7817.1232.691.43--0.141727.3352.4615.7281.0323.11132.76--
Hangzhou Alltest Biotech Co Ltd812.78m276.54m5.33bn1.09k19.211.34--6.553.503.5010.2650.020.1982.216.97743,626.506.7423.357.2226.8353.6958.3434.0339.0710.46--0.002229.79-77.7332.59-84.7526.1972.77--
Shanghai Sanyou Medical Co Ltd434.20m37.87m5.36bn466.00150.612.80--12.340.14320.14321.717.690.19510.61915.15931,756.402.099.422.4110.8570.7287.1510.7329.783.27--0.013516.21-29.0815.67-49.918.99-15.60--
Data as of Sep 13 2024. Currency figures normalised to Hangzhou AGS MedTech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.69%Per cent of shares held by top holders
HolderShares% Held
Purekind Fund Management Co., Ltd.as of 30 Jun 2024439.89k1.08%
Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024303.19k0.75%
Harvest Fund Management Co., Ltd.as of 30 Jun 2024294.13k0.72%
China Southern Asset Management Co., Ltd.as of 30 Jun 2024147.88k0.36%
VanEck Australia Pty Ltd.as of 04 Oct 202479.80k0.20%
Nuode Asset Management Co., Ltd.as of 30 Jun 202464.87k0.16%
Orient Securities Asset Management Co. Ltd.as of 30 Jun 202459.64k0.15%
Caitong Fund Management Co., Ltd.as of 30 Jun 202440.45k0.10%
HuaAn Fund Management Co., Ltd.as of 30 Jun 202436.22k0.09%
Tian Hong Asset Management Co., Ltd.as of 30 Jun 202434.43k0.09%
More ▼
Data from 30 Jun 2024 - 07 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.